摘要:
Methods for improving the processability of an active concentrate are disclosed. Specifically, an ionic liquid is incorporated into the diluting process to lower the viscosity and avoid the formation of a viscosity-increasing gel phase. Moreover, the ionic liquid may comprise an ion active capable of delivering a desired benefit, which accompanies and/or enhances the benefit provided by the active in the concentrate. The present invention also encompasses a dilution process for forming a product composition from a conventional active concentrate or an ionic liquid containing composition. The present invention further comprises compositions made by these processes.
摘要:
Compositions comprising an ionic liquid active composed of an ion active and an ionic liquid-forming counter ion, wherein the ion active is capable of delivering a fabric treating benefit, a surface treating benefit, and/or an air treating benefit. The compositions are substantially free of added water and have a viscosity less than about 5000 mPa·s at room temperature. The compositions are easily diluted with water and/or organic solvent, without formation a gel phase during the dilution process. Various products, especially a unit dose product, made with such compositions are also disclosed.
摘要:
A system for monitoring and configuring gaming devices interconnected over a high-speed network. Each gaming device includes a data communication node which allows the gaming device to communicate with a floor controller over a current loop network. The data communication network communicates with both the floor controller and the gaming device. In a multiple jackpot time bonus, the system activates a storm simulator which provides simulated lightning and thunder that vary in intensity with the value of a jackpot multiplier during a bonus period. The bonus jackpots are paid to players at the gaming device.
摘要:
The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.